02xl is your source for accurate and trustworthy information so you can make the best choices for your health and wellness.
PS: Please note that 02xl provides this information for the benefit of the rare disease and overweight community. 02xl is not a medical provider or health care facility and thus can neither diagnose any disease or disorder nor endorse or recommend any specific medical treatments. Patients must rely on the personal and individualized medical advice of their qualified health care professionals before seeking any information related to their particular diagnosis, cure or treatment of a condition or disorder.
The European Union has approved ChemoCentryx Inc’s (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis.
-
The approval follows the FDA approval of Tavneos in October 2021.
-
The approval covers the treatment combined with a rituximab or cyclophosphamide regimen for severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis.
-
Related: EXCLUSIVE: ChemoCentryx Plans To Start Phase 3 Avacopan Trial In Chronic Skin Disorder In 2022.
-
As part of their Kidney Health Alliance, ChemoCentryx retains all rights for avacopan for orphan and renal diseases in the U.S., and Vifor Pharma has rights to commercialize avacopan in the rest of the world.
-
Vifor will pay ChemoCentryx royalties in the teens to the mid-20s percent on potential ex-U.S. sales of one aggregate net sales line.
-
Price Action: CCXI shares are up 3.84% at $31.88 during the market session on the last check Wednesday.
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.